Gilgamesh Pharma Raises $60M Series A to Advance Psychedelic-Derived Therapies
Funding Details
$60M
Series A
Most biotech stories try to sound like breakthroughs before they’ve earned it. Gilgamesh Pharma moves different. The signal shows up in the data, the deals, and who’s writing the checks when it’s time to get serious. Fresh off a spinout that followed AbbVie’s up to $1.2B acquisition of bretisilocin, Gilgamesh Pharma just pulled in $60M Series A led by Satori Neuro, with Prime Movers Lab back at the table like seasoned regulars who already know how the kitchen operates. That’s not luck. That’s pattern recognition with a checkbook.
Jonathan Sporn, MD, Founder and CEO, has been around enough drug development cycles to know where bodies are buried and where breakthroughs hide. Andrew Kruegel, PhD, Co-Founder and CSO, is the kind of chemist who doesn’t just study compounds, he speaks their language. Together, they’re not remixing old science, they’re engineering new chemical entities with the kind of IP backbone that actually holds weight when the stakes get real.
And the stakes are real. Neuropsychiatric disorders aren’t some niche corner of medicine. They’re massive, stubborn, and expensive. Gilgamesh Pharma is leaning into psychedelic-derived and neuroplastogen therapeutics, but with a twist that matters. Oral, scalable, and engineered for safety. Translation for the non-lab crowd: this isn’t a science project, it’s a path to actual adoption.
Blixeprodil is already showing a 6.3-point improvement on MADRS at 24 hours. In this game, speed matters. Durability matters more. Effects holding through 28 days starts to shift the conversation from “interesting” to “pay attention.” Then there’s GM-3009, a cardiac-safe ibogaine analog tackling opioid use disorder without the historical baggage. That’s not iteration, that’s intent.
Satori Neuro stepping in as lead isn’t just capital, it’s conviction. Amy Kruse has seen enough cycles to know when something is signal versus noise. Prime Movers Lab returning tells you the first bet aged well.
The quiet lesson here is discipline. Spin out at the right moment. Keep the pipeline. Secure non-dilutive funding like the $14M NIDA grant. Then raise when the data starts talking louder than the deck. That’s how you stack leverage without shouting about it.